- Home
- ENTA vs FLC Comparison
ENTA vs FLC Comparison
Compare ENTA & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- FLC
- Stock Information
- Founded
- ENTA 1995
- FLC 2003
- Country
- ENTA United States
- FLC United States
- Employees
- ENTA N/A
- FLC N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- ENTA Health Care
- FLC Finance
- Exchange
- ENTA Nasdaq
- FLC Nasdaq
- Market Cap
- ENTA 164.6M
- FLC 174.2M
- IPO Year
- ENTA 2013
- FLC N/A
- Fundamental
- Price
- ENTA $7.51
- FLC $17.03
- Analyst Decision
- ENTA Buy
- FLC
- Analyst Count
- ENTA 5
- FLC 0
- Target Price
- ENTA $18.40
- FLC N/A
- AVG Volume (30 Days)
- ENTA 173.3K
- FLC 37.8K
- Earning Date
- ENTA 08-08-2025
- FLC 01-01-0001
- Dividend Yield
- ENTA N/A
- FLC 6.64%
- EPS Growth
- ENTA N/A
- FLC N/A
- EPS
- ENTA N/A
- FLC N/A
- Revenue
- ENTA $64,462,999.00
- FLC N/A
- Revenue This Year
- ENTA N/A
- FLC N/A
- Revenue Next Year
- ENTA $2.75
- FLC N/A
- P/E Ratio
- ENTA N/A
- FLC N/A
- Revenue Growth
- ENTA N/A
- FLC N/A
- 52 Week Low
- ENTA $4.09
- FLC $12.62
- 52 Week High
- ENTA $15.92
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- ENTA 51.19
- FLC 54.70
- Support Level
- ENTA $7.15
- FLC $16.83
- Resistance Level
- ENTA $8.31
- FLC $17.05
- Average True Range (ATR)
- ENTA 0.48
- FLC 0.10
- MACD
- ENTA 0.01
- FLC -0.02
- Stochastic Oscillator
- ENTA 55.73
- FLC 54.05
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.